QTRX

Quanterix Corporation

$3.28

-2.96%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation.

Source: Yahoo Finance
AI summary

Price & performance

1M+0.0%
3M+35.5%
YTD-49.0%
1Y-35.9%
52-week range—
Beta1.98
Full chart and returns against a benchmark

Q-Score

38/ 100

Quality against peers; 50 is the peer median.

Growth44
Risk42
Performance29
Valuation56
Profitability37
Leverage45
Sentiment5
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$138.9M+1.1%
Net income-$107.2M
Net margin-77.1%-49.1 pts
Historical fundamentals

Red flags in filings

2active red flags
Restated financialsNov 12, 2024
Auditor changeMay 14, 2025
Filings, findings and the timeline

Revenue exposure

Largest customer10%
Regions, segments, customers and suppliers

Valuation

QTRXIndustryP/E—29.61P/S1.053.49EV/EBITDA—18.38P/B0.713.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 9next report, before the open
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate